ERK

ERK
Name	Extracellular signal–regulated kinase
Uniprot	P28482 / P27361
Organism	Homo sapiens
Length	360 / 361
Mass	41 kDa / 44 kDa

ERK ERK is a family of mitogen-activated protein kinases involved in transmitting signals from Receptor tyrosine kinases to nuclear and cytosolic targets, coordinating proliferation, differentiation, and survival. ERK participates in canonical cascades downstream of RAS and RAF, integrates inputs from G protein–coupled receptors and Integrins, and influences transcription factors such as c-Fos, Elk-1, and c-Myc. Its dysregulation is implicated in cancers, developmental disorders, and neurodegenerative diseases, linking biochemical signaling to pathological outcomes observed in studies by groups at institutions like National Institutes of Health, Harvard University, and Stanford University.

Overview

ERK refers to mitogen-activated protein kinases MAPK1 and MAPK3, historically characterized in experiments at Cold Spring Harbor Laboratory and by researchers associated with Max Planck Institute and Imperial College London. ERK signaling is a core module within the MAPK family alongside p38 MAPK, JNK, and ERK5, and it interfaces with pathways studied in the contexts of Epidermal growth factor research and Insulin-like growth factor biology. Seminal reviews from labs at Rockefeller University and conferences at European Molecular Biology Laboratory synthesized biochemical kinetics, structural biology from groups at European Bioinformatics Institute, and genetic evidence from model organisms such as Drosophila melanogaster, Mus musculus, and Saccharomyces cerevisiae.

Structure and Isoforms

ERK proteins are ~41–44 kDa serine/threonine kinases with conserved MAP kinase domains characterized by a TEY activation motif and a docking groove recognized by MAPK kinases. Structural determination by teams at MRC Laboratory of Molecular Biology and University of Cambridge using X-ray crystallography revealed the N-terminal lobe, C-terminal lobe, and activation loop; these studies complemented NMR and cryo-EM work from University of Oxford. Two major mammalian isoforms, MAPK1 (ERK2) and MAPK3 (ERK1), were cloned in labs at Johns Hopkins University and Yale University and show differential expression patterns across tissues reported by consortia like Human Protein Atlas. Alternative splicing and post-translational modifications, documented in datasets from UniProt and GenBank, contribute to isoform-specific interactions with scaffold proteins such as KSR1, MP1, and IQGAP1.

Activation and Signaling Pathway

Activation of ERK is classically mediated by the three-tiered cascade: activation of Growth factor receptor-bound protein 2–coupled receptor tyrosine kinases leads to recruitment of Son of Sevenless guanine nucleotide exchange factors, activation of RAS GTPases, and subsequent stimulation of RAF kinases (ARAF, BRAF, CRAF). RAF phosphorylates and activates MEK1/MEK2 (MAP2K1/2), which dually phosphorylate the TEY motif on ERK, a mechanism elucidated in biochemical assays at Salk Institute and Cold Spring Harbor Laboratory. ERK phosphorylates a spectrum of substrates including transcription factors like SRF and ATF2, cytoskeletal regulators such as Myosin light-chain kinase, and metabolic enzymes investigated by groups at Massachusetts Institute of Technology and California Institute of Technology. Cross-talk with PI3K–AKT signaling, modulation by Src family kinases, and inputs from Notch signaling illustrate network integration studied in systems biology centers like Institute for Systems Biology.

Cellular Functions and Roles

ERK controls cell cycle entry via regulation of cyclin D1 and influences differentiation pathways in lineages exemplified by studies on Neural crest development, Skeletal myogenesis, and Osteoblast maturation. In neurons, ERK participates in synaptic plasticity, long-term potentiation, and memory formation as shown in experiments from Cold Spring Harbor Laboratory and University College London. In immune cells, ERK modulates cytokine production and T cell receptor signaling documented in work at Dana-Farber Cancer Institute and Karolinska Institutet. ERK-driven transcriptional programs overlap with oncogenic signatures identified in cohorts analyzed by The Cancer Genome Atlas and therapeutic response patterns reported by National Cancer Institute clinical trials.

Regulation and Feedback Mechanisms

ERK activity is constrained by phosphatases including DUSP6, PP2A, and nuclear MKPs characterized by researchers at Weill Cornell Medicine and Vanderbilt University. Scaffold proteins such as KSR1 and β-Arrestin organize spatial signaling microdomains; endocytic trafficking via Clathrin and Caveolin-1 regulates signal duration. Negative feedback from ERK to upstream nodes (e.g., phosphorylation of SOS or RAF) and transcriptional induction of dual-specificity phosphatases form homeostatic loops described in models from Los Alamos National Laboratory and computational studies at European Bioinformatics Institute. Mutations in regulatory components, explored in genetics labs at Broad Institute and Wellcome Sanger Institute, perturb these feedbacks with functional consequences.

Clinical Significance and Disease Associations

Aberrant ERK signaling underlies oncogenesis in malignancies driven by activating mutations in BRAF (notably V600E) and KRAS; these insights have informed targeted therapies such as vemurafenib and trametinib developed through collaborations among GlaxoSmithKline, Roche, and academic drug discovery centers. Developmental disorders termed RASopathies—including Noonan syndrome and Cardio-facio-cutaneous syndrome—trace to germline alterations affecting the ERK pathway reported by pediatric genetics groups at Great Ormond Street Hospital and Children's Hospital of Philadelphia. Neurodegenerative and psychiatric conditions, including studies of Alzheimer's disease and Schizophrenia cohorts, implicate ERK dysregulation in synaptic dysfunction. Resistance mechanisms to MAPK pathway inhibitors studied in translational programs at MD Anderson Cancer Center and combination strategies integrating immunotherapy investigated at Memorial Sloan Kettering Cancer Center continue to shape clinical management.

Category:Protein kinases